European Union drug regulators discovered no evidence that extremely in style weight loss and diabetes drugs equivalent to Wegovy and Ozempic are linked to an elevated danger of suicidal thoughts and self-injury, the regulator stated Friday. 

The European Medicines Company performed a nine-month investigation into so-called GLP-1s, a blockbuster class of remedies that mimic a hormone produced within the intestine to suppress an individual’s urge for food. These medicine have skyrocketed in demand over the past 12 months regardless of their hefty worth tags and spotty insurance coverage protection.

The assessment examined a number of medicine from Novo Nordisk, together with Wegovy and Ozempic. It didn’t embody Eli Lilly‘s Zepbound and Mounjaro, two variations of the identical drug offered for weight reduction and diabetes. However the probe did embody the energetic ingredient in an older diabetes remedy from Eli Lilly known as Trulicity. 

Novo Nordisk didn’t instantly reply to a request for touch upon the EMA’s findings.

The company’s verdict is the newest in a collection of reassuring reviews on suicide danger for GLP-1s. The U.S. Meals and Drug Administration got here to an identical conclusion in January however stated company officers could not definitively rule out {that a} “small danger could exist.” 

Scientific trials from Novo Nordisk and Eli Lilly haven’t demonstrated a hyperlink between GLP-1s and suicidal ideas. Nonetheless, researchers and docs have been looking out for any new undesirable unintended effects or added dangers as hundreds of latest sufferers begin taking the medicine. 

The EMA first launched its investigation in July after the Icelandic Medicines Company flagged three instances of suicidal ideas and self-injury in sufferers taking medicine containing liraglutide and semaglutide, the energetic substances within the in style remedies.

Semaglutide is the energetic ingredient utilized in Wegovy, Ozempic and Novo Nordisk’s diabetes tablet Rybelsus. Liraglutide is the energetic ingredient in Novo Nordisk’s older weight reduction drug Saxenda. The probe additionally included different energetic substances in older weight reduction and diabetes medicine, together with dulaglutide, exenatide and lixisenatide. 

The EMA on Friday stated it analyzed outcomes from a big U.S. examine and didn’t discover a direct affiliation between the usage of semaglutide and suicidal ideas. Outcomes from one other examine performed by the company additionally didn’t assist a hyperlink between GLP-1 medicine and the chance of suicidal ideas. 

Each the research have been primarily based on digital well being information.

If you’re having suicidal ideas or are in misery, contact the Suicide & Crisis Lifeline at 988 within the U.S. or the Samaritans within the U.Okay. at 116 123 for assist and help from a skilled counselor.